JAMA
Original Investigation
November 18, 2024
Caihua聽Sang,聽MD; Qiang聽Liu,聽MD; Yiwei聽Lai,聽MD; Shijun聽Xia,聽MD; Ruhong聽Jiang,聽MD; Songnan聽Li,聽MD; Qi聽Guo,聽MD; Qifan聽Li,聽MD; Mingyang聽Gao,聽MD; Xueyuan聽Guo,聽MD; Lihong聽Huang,聽MD; Nian聽Liu,聽MD; Chenxi聽Jiang,聽MD; Song聽Zuo,聽MD; Xiaoxia聽Liu,聽MD; Mengmeng聽Li,聽MD; Weili聽Ge,聽MD; Shangming聽Song,聽MD; Lianghua聽Chen,聽MD; Shuanglun聽Xie,聽MD; Jiangang聽Zou,聽MD; Ke聽Chen,聽MD; Xiangfei聽Liu,聽MD; Hesheng聽Hu,聽MD; Xinhua聽Wang,聽MD; Jinlin聽Zhang,聽MD; Zhaojun聽Wang,聽MD; Chi聽Wang,聽MPH; Liu聽He,聽PhD; Chao聽Jiang,聽MD; Ribo聽Tang,聽MD; Ning聽Zhou,聽MD; Yunlong聽Wang,聽MD; Deyong聽Long,聽MD; Xin聽Du,聽MD; Chenyang聽Jiang,聽MD; Laurent聽Macle,聽MD; Jianzeng聽Dong,聽MD; Changsheng聽Ma,聽MD; PROMPT-AF investigators
free access
JAMA. 2024; 10.1001/jama.2024.24438
This clinical trial evaluates whether linear ablation combined with ethanol infusion of the vein of Marshall and pulmonary vein isolation (PVI) is more effective than PVI alone in patients with persistent atrial fibrillation.
JAMA
Editorial
November 18, 2024
Miguel聽Valderr谩bano,聽MD, PhD
free access
JAMA. 2024; 10.1001/jama.2024.24601
JAMA Pediatrics
Original Investigation
November 18, 2024
Lex W.聽Doyle,聽MD; Rheanna聽Mainzer,聽PhD; Jeanie L. Y.聽Cheong,聽MD
JAMA Pediatr. 2024; 10.1001/jamapediatrics.2024.4575
This comparative effectiveness research assesses differences in the association of systemic postnatal corticosteroids with survival free of cerebral palsy by risk of bronchopulmonary dysplasia.
JAMA Pediatrics
Comment & Response
November 18, 2024
Ola Didrik聽Saugstad,聽MD, PhD
JAMA Pediatr. 2024; 10.1001/jamapediatrics.2024.4827
JAMA Pediatrics
Comment & Response
November 18, 2024
Alison聽Gemmill,聽PhD, MPH; Suzanne O.聽Bell,聽PhD
JAMA Pediatr. 2024; 10.1001/jamapediatrics.2024.4830
JAMA
Viewpoint
November 18, 2024
Michael J.聽Barry,聽MD; Michael聽Silverstein,聽MD, MPH; Wanda聽Nicholson,聽MD
JAMA. 2024; 10.1001/jama.2024.22537
This Viewpoint summarizes how the US Preventive Services Task Force specifies target populations for its recommendations and highlights 3 problems鈥攊ncluding exacerbation of health inequities鈥攑osed by the proposed use of more complex risk models to better identify target populations and increase effectiveness and efficiency of prevention efforts (鈥減recision prevention鈥).
JAMA
Comment & Response
November 18, 2024
Brian聽Lipworth,聽MD; Mintu聽Nath,聽PhD; Graham聽Devereux,聽MD
JAMA. 2024; 10.1001/jama.2024.20750
JAMA
Comment & Response
November 18, 2024
Chi-Kuei聽Hsu,聽MD; Chih-Cheng聽Lai,聽MD
JAMA. 2024; 10.1001/jama.2024.20747
JAMA
Research Letter
November 18, 2024
Alexander E.聽Soltoff,聽BS; Mark Aaron聽Unruh,聽PhD; David G.聽Stevenson,聽PhD; Dio聽Kavalieratos,聽PhD; Robert Tyler聽Braun,聽PhD
JAMA. 2024; 10.1001/jama.2024.20546
This study compares differences in caregiver-reported hospice quality across categories of ownership, including for-profit private equity firm (PEF)/publicly traded company (PTC)鈥搊wned and non-PEF/PTC鈥搊wned hospices as well as not-for-profit鈥搊wned hospices.